In his weekly clinical update, Dr. Griffin discusses a microbiologist who was harassed during COVID pandemic sues university, use of inactivated poliovirus vaccine for poliovirus outbreak response, safety and immunogenicity of bivalent rsvpref vaccine coadministered with seasonal inactivated influenza vaccine in older adults, coffee as a dietary strategy to prevent SARS-CoV-2 infection, enrollment of pediatric patients in COVID-19 interventional trials, vaccination, immunity, and the changing impact of COVID-19 on infant health, COVID-19 vaccine effectiveness against post- COVID -19 condition among 589722 individuals in Sweden, repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting, protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults, the Novavax heterologous COVID booster demonstrates lower reactogenicity than mRNA vaccines, T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19, oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China, and how COVID-19 convalescent plasma therapy decreases inflammatory cytokines, therapeutic heparin in non-ICU patients hospitalized for COVID-19 in the ACTIV-4a trial. Click arrow to play Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Microbiologist who was harassed during COVID pandemic sues university (Nature) Use of inactivated poliovirus vaccine for outbreak response (The Lancet) Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with Influenza vaccine (CID) Coffee as a dietary strategy to prevent SARS-CoV-2 infection (BMC) Enrollment of pediatric patients in COVID-19 interventional trials (JAMA) Vaccination, immunity, and the changing impact of COVID-19 on infant health (PNAS) COVID-19 vaccine effectiveness against post- COVID -19 condition (BMJ) Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting (Nature) Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes (CID) Novavax heterologous COVID booster demonstrates lower reactogenicity than mRNA (JID) T-cell responses to SARS-CoV-2 infection and vaccination reduce risk of severe COVID-19 (STM) Oral VV116 vs placebo in patients with mild-to-moderate COVID-19 in China (The Lancet) COVID-19 convalescent plasma therapy decreases inflammatory cytokines (MS) Therapeutic heparin in non-ICU patients hospitalized for COVID-19 in the ACTIV-4a trial (Chest) Contribute to our MicrobeTV fundraiser at PWB Letters read on TWiV on TWiV 1066 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]